Intra-Cellular Therapies Inc. - Common Stock (ITCI)
Frequently Asked Questions About Intra-Cellular Therapies Inc. - Common Stock (ITCI)
How does Intra-Cellular Therapies approach drug development?
The company employs a targeted approach to drug development that focuses on understanding the underlying biological mechanisms of neuropsychiatric disorders. This involves leveraging insights from neuroscience, pharmacology, and clinical research to design and optimize drug candidates tailored to specific patient needs.
How does Intra-Cellular Therapies ensure drug safety?
The company ensures drug safety through rigorous clinical testing as mandated by regulatory agencies like the FDA. By adhering to Good Clinical Practice (GCP) guidelines and closely monitoring trial participants for adverse effects, Intra-Cellular Therapies aims to demonstrate that its treatments are not only effective but also safe for patients.
How has Caplyta performed since its launch?
Since its launch, Caplyta has received positive feedback from healthcare providers and patients, contributing to an increasing market share in the antipsychotic landscape. The drug's favorable tolerability and efficacy have bolstered its commercial success and positioned it as an important treatment option for schizophrenia.
Is Intra-Cellular Therapies involved in any philanthropic efforts?
Intra-Cellular Therapies is committed to social responsibility and engages in philanthropic efforts aimed at supporting mental health awareness and education. Through collaborations with various nonprofit organizations, the company seeks to contribute to community initiatives that improve mental health services and support research in psychiatry.
Is Intra-Cellular Therapies publicly traded?
Yes, Intra-Cellular Therapies is publicly traded on the NASDAQ stock exchange under the ticker symbol ITCI. The company went public in 2013 and has since aimed to grow its investor base as it advances its drug development programs.
What are the clinical trial stages of Intra-Cellular Therapies' drugs?
Intra-Cellular Therapies conducts clinical trials in multiple stages, including Phase 1 for safety and dosage, Phase 2 for efficacy and side effects, and Phase 3 for further validation of efficacy in larger populations. The company's approach to clinical trials is designed to ensure rigorous testing and adherence to regulatory requirements.
What are the key products of Intra-Cellular Therapies?
The leading product of Intra-Cellular Therapies is Caplyta (lumateperone), which is approved by the FDA for the treatment of schizophrenia in adults. The company is also exploring additional therapeutic candidates in its pipeline for various neuropsychiatric conditions, including bipolar disorder and major depressive disorder.
What challenges does Intra-Cellular Therapies face?
Intra-Cellular Therapies faces challenges typical in the biopharmaceutical industry, including regulatory hurdles, competition from other drug manufacturers, and the need for ongoing funding for research and development. Additionally, market acceptance and physician education regarding new therapies can also impact business growth.
What diseases are targeted by Intra-Cellular Therapies' pipeline?
Intra-Cellular Therapies targets various neuropsychiatric diseases through its pipeline, including schizophrenia, bipolar disorder, major depressive disorder, and other mood disorders. Their commitment to addressing these conditions reflects the significant unmet needs in mental health care.
What does Intra-Cellular Therapies Inc. do?
Intra-Cellular Therapies Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for neuropsychiatric diseases. They aim to address unmet medical needs through their proprietary drug development platform, which utilizes insights into cellular and molecular pathways to create novel treatments primarily targeting conditions like schizophrenia and mood disorders.
What financial information is important for investors?
Investors should pay attention to key financial metrics such as revenue growth, net income or losses, cash reserves, and R&D expenditures. Intra-Cellular Therapies provides updates on its financial performance quarterly, which can give insight into the company's operational efficiency and investment potential.
What is the importance of the company's research and development (R&D)?
R&D is crucial for Intra-Cellular Therapies, as it underpins the company's long-term growth and success by facilitating the discovery of new treatments. Effective R&D enables the company to innovate within its therapeutic areas, maintain a competitive edge in the market, and fulfill its mission of addressing unmet medical needs in mental health.
What is the research focus of Intra-Cellular Therapies?
Intra-Cellular Therapies focuses its research on understanding the biology of neuropsychiatric disorders and developing innovative treatments based on this understanding. Their research encompasses cellular signaling pathways and neurotransmitter systems, enabling the company to target multiple aspects of these complex diseases effectively.
What is the significance of Caplyta?
Caplyta is significant as it represents a novel approach to treating schizophrenia, with a unique mechanism of action that differentiates it from existing antipsychotic medications. Its approval by the FDA marked a major milestone for Intra-Cellular Therapies and offers patients a new treatment option with a potentially better side effect profile.
What is the vision of Intra-Cellular Therapies?
Intra-Cellular Therapies' vision is to transform the treatment landscape for patients with neuropsychiatric conditions by developing innovative therapies that improve outcomes and quality of life. The company is dedicated to addressing the significant unmet needs in mental health care and providing hope to patients and their families.
What partnerships does Intra-Cellular Therapies have?
Intra-Cellular Therapies has established partnerships with academic institutions, research organizations, and other biopharmaceutical companies to enhance its research and development capabilities. Collaborations often focus on advancing preclinical and clinical-stage programs while facilitating the sharing of knowledge and resources.
When was Intra-Cellular Therapies founded?
Intra-Cellular Therapies was founded in 2002. Since its inception, the company has focused on discovering and developing novel therapies for psychiatric and neurologic diseases, leveraging expertise in cellular signaling and drug development.
Where is Intra-Cellular Therapies headquartered?
Intra-Cellular Therapies is headquartered in New York City, New York. The location allows the company to attract talent and collaborate with leading academic institutions and medical centers in the region.
Who are the key executives at Intra-Cellular Therapies?
The executive team at Intra-Cellular Therapies includes Dr. Sharon Mates, who serves as Chairman and CEO, and other experienced leaders in the biopharmaceutical industry. Together, they bring a wealth of knowledge in drug development, commercialization, and corporate management to drive the company's mission forward.
What is the current price of Intra-Cellular Therapies Inc. - Common Stock?
The current price of Intra-Cellular Therapies Inc. - Common Stock is 131.87
When was Intra-Cellular Therapies Inc. - Common Stock last traded?
The last trade of Intra-Cellular Therapies Inc. - Common Stock was at 4:00 pm EDT on April 1st, 2025
What is the market capitalization of Intra-Cellular Therapies Inc. - Common Stock?
The market capitalization of Intra-Cellular Therapies Inc. - Common Stock is 12.44B
How many shares of Intra-Cellular Therapies Inc. - Common Stock are outstanding?
Intra-Cellular Therapies Inc. - Common Stock has 94.32M shares outstanding.